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Introduction
Fungi have beneficial roles in human affairs such as in production of food, as symbionts, and in nutrient cycling. Fungi also have significant harmful effects on human health, agriculture, and in food and materials spoilage. As examples, the rice blast fungus, Magnaporthe grisea (Hebert) Barr (Magnaporthaceae), destroys millions of tons of rice each year (Valent, 2004) , and other fungi cause mycoses that result in livestock loss and increased health care costs. Control strategies that include the use of antifungals are therefore required to limit which, when, and where fungi grow in our environment. Currently, six main classes of antifungals exist: echinocandins, griseofulvins, polyene macrolides, fluorinated pyrimidines, allylamines, and azole derivatives (Francois et al., 2005) . Widespread use of selected antifungals has led to an increase in the incidence of drug-resistant fungal strains. This, along with a limited effectiveness of antifungals against some pathogenic fungi, has emphasized a need to develop new antifungals with different activity spectra. The development of new antifungals is complicated because, as eukaryotes, fungi are evolutionarily related to plants and animals (Anderson, 2005) . Therefore, suitable antifungals must have a high index of specificity so that they affect fungal-specific processes and do not harm nontarget species. In this respect, it is desirable to obtain antifungals that interfere with diverse, essential, fungalspecific pathways and/or that target multiple pathways so that resistance is unlikely to readily arise. Consequently, the initial process of antifungal discovery involves recognition of possible leads and characterization of the compound, including specificity and mode of action determinations. Plant-derived compounds offer promising leads in the discovery of new and effective antifungals. Several plantderived antifungals have been described (review in Cowan, 1999) . Many of these antifungals are secondary metabolites that are likely produced by the plant as a defense against fungal pathogens. Clearly, there has been a strong evolutionary pressure on plants to develop chemical defense strategies that are not readily overcome by pathogen resistance mechanisms. Traditional healers have long recognized antiseptic properties of specific plant species, and this knowledge base serves as a useful starting point in the discovery process. For example, in a study by Arnason's group (Jones et al., 2000) , it was found that plants used most often for treating infection-like symptoms by First Nations Peoples of eastern Canada had higher overall antifungal activities than medicinal plants used for other purposes.
Once identified, isolation and characterization of antifungal compound(s) from a plant is effectively done through bioassay-guided fractionation, a process by which a crude plant extract is fractionated based on chemical characteristics (solubility, polarity, etc.) and each fraction is subsequently assayed for antifungal activity (Ficker et al., 2003) . Activity can be measured using methods such as disk diffusion and broth dilution assays. In addition, high-throughput methods involving gene deletion arrays (GDAs) and DNA microarrays are being developed to elucidate mode of action of antifungals. GDA analysis, in particular, holds promise in antifungal mode of action determinations. GDA based on the yeast Saccharomyces cerevisiae Meyen ex. E. C. Hansen (Saccharomycetaceae) consists of inoculating each of ∼4700 viable deletion mutants onto medium containing quasi-inhibitory concentrations of the test compound followed by growth analyses of each mutant after a suitable incubation period. A synthetic sick phenotype results from the combination of a specific gene deletion and a chemical interaction (Tong et al., 2004) . Recognition of this synthetic sick phenotype can be automated by digital analysis of colony size (Memarian et al., 2007) . Inferring mode of action from GDA data sets requires analysis of the function of knockout genes in supersensitive mutants followed by identification of candidate parallel pathways that may be disrupted by the chemical. Mode of action using this approach was demonstrated with rapamycin, a naturally occurring drug produced by Streptomyces hygroscopicus (Jensen) Waksman and Henrici (Streptomycetaceae) (Xie et al., 2005) and is ongoing with several ethnobotanical compounds including those found in Echinacea, and with chimaphilin and berberine (Mirrashed, 2007; Smith, Arnason, Golshani et al., personal communication) . Recent developments to automate this data analysis step will provide rapid inference on mode of action from GDA experiments (Dumontier, 2006) . Aside from the complexity of identifying antifungal mode of action from GDA data sets, the incidence of false positives associated with highthroughput assays must be acknowledged. It is therefore desirable to test hypotheses on mode of action obtained in primary assays using secondary assays. Secondary assays to verify antifungal mode of action are not standardized, and the methods are dispersed in the literature. The goal of this study is to initiate a compendium of secondary assays that evaluate antifungal mode of action. Assays are developed that set out to test the in vivo effects of phytochemicals on fungal mRNA transcription, cell wall integrity, and antioxidant activities, and additional assays are reviewed.
Materials and Methods

General methods
Echinacea purpurea (L.) Moench (Asteraceae) roots were extracted and fractionated as described in Hudson et al. (2005) . Chimaphilin was purified from dried Chimaphila umbellata (L.) W. Bart (Pyrolaceae) as described by Galván et al. (Galván et al., 2007) . Nordihydroguaiaretic acid (NDGA) and ascorbic acid were obtained from Calbiochem (Darmstadt, Germany). Four S. cerevisiae strains were used in this study: S288C (MATα SUC2 gal2 mal mel flo1 flo8-1 hap1; Mortimer & Johnston, 1986) 
Transcriptional activity assay
For this assay, we used strain YBR115C expressing the construct pUKC815 that contained the β-galactosidase reporter gene. Mid-log phase cells were grown in SCura with subinhibitory amounts of chimaphilin, or with the carrier control (EtOH), for 4 h at 30
• C. Yeast cells were harvested by centrifugation, resuspended in Z-buffer (60 mM Na 2 HPO 4 , 40 mM NaH 2 PO 4 , 10 mM KCl, 1 mM MgSO 4 ·7H 2 O, 0.27% β-mercaptoethanol, pH 7.0) and kept on ice. Initial cell density was measured at OD 600 , and β-galactosidase activity was measured as described by Miller (1972) . Briefly, 20 µL of 0.1% SDS and 50 µL of chloroform were added to each sample, equilibrated in a 30
• C water bath, and mixed with 200 µL of prewarmed ONPG (o-nitrophenyl-β-D-galactopyranoside, 4 mg/mL in 0.1 M potassium phosphate; Sigma-Aldrich). The reaction was stopped with 500 µL of 1 M Na 2 CO 3 . The cell debris was removed by centrifugation and units of β-galactosidase activity was quantified spectrophotometrically using the following equation: U = 1000[OD 420 -(1.75 · OD 550 )/(10 (t· V · OD 600 )], where V is volume (mL) of cell suspension used and t is time in minutes.
Cell wall integrity assays
Yeast strain S228C was grown overnight in YPD to midlog phase and adjusted to approximately 10 4 cells/mL. The culture (2 mL) was transferred to a disposable culture tube and incubated overnight with gentle shaking at 30
• C with either chimaphilin (3.0 µg/mL) or Echinacea extract (1.42 mg/mL of 70% EtOH extract). Controls consisted of cultures to which the equivalent volume of carrier solvent (EtOH) was added without compound. After incubation, the cell density was adjusted to 10 7 cells/mL. Cell wall disruption was done either by heat shock treatments in a 65
• C water bath for 0, 30, 40, and 50 s or by sonication (Vibra-Cell, Sonics and Materials, Danbury, CT, USA) at a 3-µm amplitude for durations of 0, 135, and 140 s. After heat shock or sonication treatments, cell viability was estimated by drop-plate assays as described in Chen et al. (2003) using a 10-fold dilution series.
Antioxidant activity assay
The knockout mutants DAN1 [referred to as wild-type (wt) hereafter because it is not sensitive to hyperoxia] and SOD1 were grown overnight in YPD to mid-log phase and 10x serially diluted before drop-plate assays were done on YPD medium containing NDGA (0, 3.13, 6.25, 12.5, 25, 50 , and 100 µM), ascorbic acid (0, 2.5, 5, 10, 20, 40, and 80 mM), or equivalent volumes of carrier solvent (EtOH and water, respectively). Replicate plates were incubated separately under normoxic (ca. 21% O 2 ) and hyperoxic (ca. 100% O 2 ) conditions at 30
• C for 48 h at which time colony counts were done.
Results and Discussion
Reporter gene expression assay to test effects on fungal transcription
Chimaphilin (2,7-dimethyl-1,4-naphthoquinone) is an antifungal compound found in pipsissewa (C. umbellata), a plant used by First Nations Peoples of eastern Canada to treat infections (Arnason et al., 1981; Jones et al., 2000) . Previously, a GDA analysis revealed that mutations in genes involved in mRNA transcription and cell wall functions were prevalent among those strains most sensitive to chimaphilin (Galván et al., 2007) . We used a β-galactosidase reporter gene in yeast to monitor transcriptional activity by measuring o-nitrophenol production from o-nitrophenyl-β-D-galactoside (ONPG). The addition of chimaphilin to yeast cells resulted in a reduction of β-galactosidase activity in a dose-dependent manner (Fig. 1) . Figure 1 . Chimaphilin-associated inhibition of β-galactosidase reporter gene expression in S. cerevisiae. Activity of β-galactosidase in YBR115C was significantly reduced at 7.5 µg/mL and 15 µg/mL of chimaphilin (bottom, open bars) relative to controls (closed bars). β-Galactosidase activity is expressed as mean (n = 3 to 5, + SD). The chimaphilin concentrations used do not significantly reduce growth rates of yeast (top: squares = chimaphilin treatments, circles = controls).
Addition of 0.3 µg/mL of chimaphilin had a small effect in reducing o-nitrophenol production by yeast cells (p = 0.40), whereas at concentrations of 7.5 and 15 µg/mL, a significant reduction was observed, compared with the carrier solvent controls (p = 0.01 and p =<0.001, respectively; paired t-test). To verify that chimaphilin concentrations used were subinhibitory to growth, cell density was measured before and after assay and used to calculate growth rates (Fig. 1) . There was no significant difference in growth rates of the cells (p = 0.43) at the chimaphilin and EtOH (control) concentrations used. Therefore, chimaphilin appears to inhibit β-galactosidase expression, consistent with the hypothesis that chimaphilin interferes with mRNA transcription processes. However, from these experiments, we cannot rule out the possibility that chimaphilin interferes with protein synthesis. Additional assays that set out to monitor whether a compound inhibits protein synthesis, as described below, could offer additional insight into chimaphilin's mode of action. More directly, developing an RT-PCR assay that will determine transcription rates in cells exposed to chimaphilin is worthwhile given the results presented here. Such RT-PCR methods are highly quantitative and fast but otherwise similar to those that used Northern analysis to test the mode of action of azoxybacilin (Aoki et al., 1996) .
Cell wall integrity assays
The cell wall is an obvious fungal-specific target for antifungal development. Fungal cell walls are composed primarily of β-glucans and chitin and are integral to survival of most free-living fungi (Debono & Gordee, 1994) . Traditionally, incorporation of calcofluor white into the growth medium has been used to assay for fungal cell wall mutants (Ram et al., 1994) . Calcofluor white binds to cell walls and appears to inhibit cell wall biogenesis or other functions. Mutants that are viable but defective in some cell wall factors have increased sensitivity to and grow poorly in the presence of calcofluor white (Ram et al., 1994) . This assay may not be suitable for evaluating antifungal effects on cell walls, however, as both calcofluor white and the antifungal compound must be added to the growth medium and this could result in synergistic or confounding interactions. It is therefore desirable to assay for cell wall integrity using physical stress. To test hypotheses based on previous GDA experiments that chimaphilin and Echinacea extracts interfere with cell wall-related processes, we used heat shock-based and sonication-based assays.
To examine cell wall integrity in yeast challenged with chimaphilin, S288C cells were grown overnight in the presence of subinhibitory (3.0 µg/mL) levels of chimaphilin or, as controls, in an equivalent volume of the carrier solvent (95% EtOH). Cultures were then heat shocked at 65
• C and cell viability was estimated by drop-plate assays on YPD plates. Figure 2 shows how the combination of chimaphilin with 30 or 40 s of exposure to 65
• C, reduced the number of viable cells by 10-fold compared with the EtOH control. With 50 s of 65
• C treatment, viable cells no longer occurred in either the chimaphilin-or EtOH-treated cultures. The increased sensitivity to the shorter heat shock durations used supports the hypothesis that chimaphilin interferes with fungal cell wall functions. A rapid thermal expansion of cells likely results in increased frequencies of death when cell wall integrity is compromised through chimaphilin exposure. From these observations, it cannot be ruled out that proteins involved in heat shock recovery may be targets of Figure 2 . Drop-plate assays of S288C treated with 3.0 µg/mL of chimaphilin followed by heat shock at 65
• C. This assay suggests a loss of cell wall integrity occurs when yeast cells are exposed to chimaphilin (Ch) compared with controls (CC). chimaphilin. This is unlikely, however, as GDA analysis did not reveal interactions between chimaphilin and heat shock proteins.
E. purpurea root extracts are also hypothesized to inhibit fungal cell wall functions based on previous GDA experiments (Mirrashed, 2007) . We tested this hypothesis using a sonication assay on yeast S228C cells grown overnight in concentrations of E. purpurea extract that caused a 20% reduction in growth rate. Sonication was previously described as an efficient assay to screen for cell wall mutants (Ruiz et al., 1999) . Treated cells sonicated for 2.15 and 2.30 min showed a marked reduction in cell viability based on dropplate assays compared with cells grown in the presence of equivalent volumes of the 70% EtOH carrier solvent (Fig. 3) . The results of this sonication assay and heat shock assays (data not shown) were congruent, and both lend support to the hypothesis that E. purpurea extracts interfere with cell wall functions.
Further studies are required to reveal the cell wall target(s) of chimaphilin and Echinacea extracts. For this purpose, enzymes involved in cell wall biogenesis can be assayed in vitro using previously described methods. Such approaches may require considerable trial and error, but may be effective in high-throughput screens. For example, the targets of the triterpene glycoside FR227244 were investigated using an in vitro enzymatic assay containing glucan or chitin synthase that monitored the incorporation of radiolabeled UDP-glucose into cell wall subunits (Kobayashi et al., 2004) . Monitoring cell permeability with fluoresecent dyes such as Sytox green may provide further indications of cell wall defects caused by antifungals (Munoz et al., 2006) . A judicious approach involves the use of multiple different assays to test hypotheses on mode of action as cellular processes are complex and highly interrelated. Cell wall defects, for example, could result from specific transcriptional or translational alterations or from perturbations to polymerization, deposition, or stabilization processes involving cell wall components. It is also important to keep in mind that plant-based antifungals may inhibit multiple unrelated cellular processes. This would be an appropriate strategy to avoid pathogen resistance mechanisms.
In vivo antioxidant assays
Wound healing is a complex process that can be enhanced by application of antibiotics and other biologically active compounds such as antioxidants. In addition, several antioxidants, such as NDGA, have been shown to have a synergistic effect when combined with an antifungal (Beggs et al., 1978) . NDGA is the primary antioxidant found in the creosote bush [Larrea tridentate (Sessé & Moc. ex DC.) Coville (Zygophyllaceae)], which has been used in traditional medicine against at least 50 ailments including kidney stones, diabetes, inflammation, and arthritis (Arteaga et al., 2005) . Previous studies also confirmed NDGA as an antifungal against pathogenic fungi (Beggs et al., 1978; Martinez-Tellez et al., 2005) and that it has antioxidant activity in vitro and in vivo (Harper et al., 1999) . We examined antioxidant activities of subinhibitory levels of NDGA using an oxidative stress assay with SOD1 , a superoxide dismutase knockout strain. The SOD1 mutant does not normally grow under hyperoxic conditions as evident from drop-plate assays in which cells were incubated for 2 days under 100% oxygen conditions (Fig. 4A) . Growth of both wild-type and SOD1 strains occurs under normoxia (Fig. 4B) . As a positive antioxidant control, ascorbic acid was included in the medium and clearly remediated hyperoxic sensitivity of SOD1 cells ( Fig. 4A; Krzepilko Figure 4 . The effects of ascorbic acid and NDGA on wild-type (WT) and SOD1 -defective strain growth under normoxia and hyperoxia. Drop-plates of WT and SOD1 strains grown (A) under hyperoxia where growth of SOD1 is remediated by ascorbic acid and (B) under normoxia where both strains grow regardless of additives used. (C) Plot showing how NDGA does not remediate hyperoxia sensitivity of SOD1 whereas ascorbic acid does. Relative concentrations are given at bottom, where "x" is 6.25 µL carrier solvent (water and EtOH for ascorbic acid and NDGA), with 2.5 mM ascorbic acid or 3.125 µM NDGA. In vivo This study Heat shock-treated cells followed by CFU determination.
CW integrity
In vivo Ruiz et al., 1999 Sonication followed by cell damage assessment by flow cytometry.
CW synthesis
In vivo Straede et al., 2007 Cell wall biosynthesis transcription factor (Rlm1p) fused to β-gal to monitor β-gal activity during cell wall stress.
In vivo Evans et al., 2002 Pico Green fluorescence measured after cells were subjected to osmotic shock. Chitin and glucan synthase inhibition Kobayashi et al., 2004 Enzyme assay measures incorporation of 14 C-UDP-glucose into the cell wall.
In vitro
1,3-β-D-Glucan synthase inhibition
In vitro Kurtz et al., 1994 Measured rate of 3 H-UDP-glucose incorporation into TCA precipitate generated by fungal cell membrane extracts. 1,3 and 1,6-β-D-Glucan synthesis inhibition
In vivo
Feldmesser et al., 2000 1,3 or 1,6-β-D-Glucan antisera used with immunoelectron microscopy.
Chitin degradation
In vitro Mavromatis et al., 2003 Antifungals incubated with chitin and reaction products observed using HPLC.
Chitin synthesis
In vivo Larcher et al., 2004 Treated cells examined microscopically for chitin deposition using FITC-conjugated wheat germ agglutinin.
CW permeation
In vivo Munoz et al., 2006 Observe uptake of Sytox green after incubation with antifungal. Cell membrane (CM) CM permeation In vivo Endo et al., 1997 Examines release of glutamine and arginine.
CM permeation
In vivo Terras et al., 1993 Quantified K + efflux from cells using atomic absorption spectrometry.
Sterol biosynthesis
In vivo Sanati et al., 1997 Quantified and identified sterols extracted from cells challenged with antifungal.
In vivo Ryder et al., 1986 Examined the incorporation of U-14 C-acetate and L-methyl-14 C-methionine into ergosterol.
In vitro Ryder et al., 1986 Examine production of ergosterol from 2 −14 C-mevalonate.
In vivo Buurman et al., 2004 ERG10 fused to β-galactosidase reporter to measure β-gal activity in response to ergosterol synthesis inhibitors.
Transcription mRNA transcription
In vivo This study β-Galactosidase reporter to examine global transcription.
RNA polymerase inhibitor
In vitro Jimenez et al., 1973 Measured incorpotation of 14 C-UTP into RNA using extracted RNA-polymerases.
Gene expression
In vivo Aoki et al., 1996 Examined expression of putative target genes using Northern blot.
Translation Protein synthesis elongation
In vitro Dominguez et al., 1998 Monitored incorporation of 14 C phenylalanine into TCA precipitate.
Aminoacyl-tRNA inhibition
In vitro Ziegelbauer et al., 1998 Monitered the incorporation of 14 C-iosleucine and 14 C-lysine into TCA precipitate using aminocyl-tRNA.
Ribosome signaling
In vivo Foiani et al., 1991 Examine alteration in ratios of ribosomal subunits.
Translation fidelity
In vivo Carr-Schmid et al., 1999 Monitor increase in β-gal activity from construct with premature stop codon.
Translation
In vivo Gaynor et al., 1994 Figure 4C , addition of ascorbic acid restores growth of SOD1 in a dose-dependent manner and completely restored hyperoxic growth of SOD1 to near wild-type levels when 80 mM ascorbic acid was added to the medium. In contrast, the addition of NDGA to the medium did not decrease sensitivity of SOD1 to hyperoxia, suggesting that NDGA is not an effective antioxidant in this in vitro assay. The apparent lack of antioxidant activity by NDGA in our assay could relate to bioavailability, as NDGA is not water-soluble. Interestingly, NDGA did not appear to inhibit yeast growth, even at the highest concentrations we assayed. Higher concentrations of NDGA, up to levels that clearly inhibit growth of yeast, should therefore be tested for antioxidant activity. There are several additional yeast knockouts involving distinct pathways from those of SOD1 that are also unable to grow under hyperoxic conditions (Golshani et al., personal communication) . It is possible, therefore, that NDGA may specifically interact with other pathways as an antioxidant, and further in vivo studies with these other mutants are recommended.
Inhibition of protein synthesis and other assays
The process of translation or protein synthesis is one of the most essential and complex cellular pathways, and because of its absolute requirement for the survival of the cell, many naturally occurring antifungals, such as hygromycin B, target this process for their activities. Consequently, it is useful to establish a systematic approach to analyze the effect of a newly identified antifungal on this process. Translation may be divided into three subcategories: ribosome biogenesis, translation fidelity, and translation efficiency. Ribosome biogenesis refers to all the pathways leading to the formation of mature ribosomes. One way to examine the effect of a target compound on ribosome biogenesis is through ribosome profile analysis (Foiani et al., 1991) . Ribosome profiling refers to the determination of the ratio of cellular ribosomal subunits to each other. A typical profile in the presence of a target compound may indicate alterations for the ratios of free 40S to 60S subunits, 40S to 80S subunits, or 40S to polysomes, as well as production of premature ribosomal subunits. Translation fidelity can be most readily studied by measuring the in vivo rate of premature stop codon read-through. This can be determined using specialized β-gal expression plasmids such as pUKC817, pUKC818, and pUKC819 (Carr-Schmid et al., 1999) , each containing a different premature stop codon in the coding regions of their β-gal genes. The presence of a bioactive compound that targets translation fidelity can increase the production of β-gal from such reporter cassettes. It is noteworthy that an increase in β-gal production in these systems may also be explained by other means such as an increase in the rate of transcription (as in the transcription assay described above). Therefore, proper controls, such as wild-type β-gal reporter plasmids, and accompanying experiments, such as determination of mRNA content, should also be considered. Other bioactive compounds may affect the rate of translation. This can be analyzed by measuring the rate of incorporation of radioactively labeled amino acids into newly synthesized proteins. The presence of 35 S-methionine in the medium (Gaynor et al., 1994 ) is the simplest and most common approach for this type of analysis. Table 1 provides a list of secondary assays used in this paper and from literature sources. The list includes assays for processes involving cell wall, cell membrane, transcription, translation, and other functions. As the study of plantbased antifungals develops, it is recommended that this compendium develop into a set of standard methods that can be used to further test mode of action.
Conclusions
The compendium initiated here is intended as a tool to guide investigations into mode of action in novel or uncharacterized antifungals. Three assays were used to examine the effects of antifungals on the cell wall and mRNA transcription in fungi. In addition, an in vivo assay was used to examine antioxidant activity of the compound NDGA. These secondary assays are based on the yeast system but can readily be adapted to test similar mode of action processes in fungal species that are more relevant to plant and animal pathology.
